PetVivo and VetStem Collaboration Enhances Animal Care Solutions
PetVivo and VetStem Join Forces to Revolutionize Veterinary Care
PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), a pioneering name in innovative veterinary medical solutions, has announced an exclusive licensing and supply agreement with VetStem, Inc. This exciting partnership focuses on the commercialization of VetStem's cutting-edge orthobiologic products, specifically the PrecisePRP® product line designed for both canines and equines.
Understanding PrecisePRP® and Its Benefits
At the heart of this collaboration is PrecisePRP®, a remarkable first-in-class off-the-shelf platelet-rich plasma (PRP) product crafted for veterinarians. This product offers a leucoreduced, allogeneic, pooled, and freeze-dried PRP solution, providing a concentrated source of platelets for intra-articular administration. The significant advantage of PrecisePRP® lies in its convenience; unlike traditional PRP kits that necessitate blood draws and centrifugation, this product is readily available for immediate use.
Uniformity and Safety in Veterinary Treatments
Consistency is critical in veterinary healthcare, and PrecisePRP® delivers just that. Each vial comes with a reliable dosage of four billion platelets, with a concentration of 500,000 platelets per microliter. Moreover, it contains fewer than 1,500 white blood cells per microliter, enhancing both safety and efficacy. Stringent screening protocols based on FDA guidance ensure that all canine and equine donors are thoroughly tested for infectious diseases and blood type. This rigorous approach minimizes the risk of transfusion reactions.
Why This Partnership is Vital for Veterinary Professionals
Industry professionals are optimistic about the collaboration's impact. Mike Eldred, a board member at PetVivo, expressed, "This is a game changer for veterinarians and their ability to treat their patients with PRP." He noted that this FDA-reviewed product will complement PetVivo’s existing technologies, such as Spryng™ with OsteoCushion™ technology. Such advances are crucial for establishing PetVivo as a leading force in veterinary medical devices and regenerative medicine.
A Vision for Regenerative Medicine
Dr. Bob Harman, CEO of VetStem, emphasized the innovation-driven ethos of PetVivo, stating that their commitment to advancing regenerative medicine for practicing veterinarians was a key factor in VetStem awarding them exclusive commercialization rights. This approach aligns perfectly with the need for practical, everyday solutions in the veterinary field.
Exploring Spryng™ with OsteoCushion™ Technology
PetVivo’s flagship product, Spryng™ with OsteoCushion™ Technology, is an injectable veterinary medical device designed specifically to manage joint-related conditions, including osteoarthritis, in various companion animals. By integrating extracellular matrix microparticles directly into the joint synovial lining, Spryng™ promotes the restoration of normal joint function. It represents an essential tool in managing the noninfectious sources of joint pain commonly faced by veterinary patients.
About PetVivo and VetStem
PetVivo Holdings, Inc. is dedicated to developing and commercializing innovative medical devices for companion animals. Their strategy focuses on adapting human medical therapies for veterinary applications, which streamlines the path to market while enhancing animal health and well-being. With a robust patent portfolio and a series of promising products, PetVivo remains committed to elevating companion animal healthcare.
On the other hand, VetStem has paved the way for regenerative medicine within the veterinary sector since its inception in 2002. Their extensive expertise in regenerative therapies has empowered countless veterinary practices with effective solutions for managing joint, tendon, and ligament ailments.
Company Communication
If you have inquiries or require further information regarding PetVivo and their innovative offerings, please reach out to:
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
Frequently Asked Questions
What is PrecisePRP®?
PrecisePRP® is an advanced platelet-rich plasma product designed for veterinary use, enabling easy access to concentrated platelets without the need for blood draws.
How does the partnership benefit veterinarians?
This collaboration allows veterinarians to utilize innovative treatments that enhance patient care and offers practical solutions to common clinical challenges.
What are the safety protocols for PrecisePRP®?
All donors are screened for infectious diseases and blood type, significantly reducing the risk of adverse reactions.
What additional technologies does PetVivo provide?
In addition to PrecisePRP®, PetVivo offers Spryng™ with OsteoCushion™ Technology, focusing on managing joint-related issues in animals.
Where can I find more information about PetVivo?
For more details about PetVivo and its products, you can reach out via email or visit their official websites.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.